

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
26 June 2008 (26.06.2008)

PCT

(10) International Publication Number
WO 2008/076437 A3

(51) International Patent Classification:

A61K 38/17 (2006.01) A61P 7/06 (2006.01)
C12N 15/62 (2006.01)

AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

(21) International Application Number:

PCT/US2007/025868

(22) International Filing Date:

19 December 2007 (19.12.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/875,682 18 December 2006 (18.12.2006) US

(71) Applicant (for all designated States except US): AC-CELERON PHARMA INC. [US/US]; 149 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): SHERMAN, Matthew, L. [US/US]; 33 Janet Road, Newton, MA 02459 (US).

(74) Agents: VINCENT, Matthew, P. et al.; Ropes & Gray LLP, One International Place, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).



Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- the filing date of the international application is within two months from the date of expiration of the priority period

(88) Date of publication of the international search report:

18 September 2008

(54) Title: ACTIVIN-ACTRII ANTAGONISTS AND USES FOR INCREASING RED BLOOD CELL LEVELS



(57) Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

WO 2008/076437 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2007/025868

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K38/17 C12N15/62 A61P7/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
R, Y	WO 2007/062188 A (ACCELERON PHARMA INC [US]; KNOPF JOHN [US]; SEEHRA JASBIR [US]) 31 May 2007 (2007-05-31) the whole document -----	1-22
Y	WO 2006/012627 A (ACCELERON PHARMA INC [US]; KNOPF JOHN [US]; SEEHRA JASBIR [US]) 2 February 2006 (2006-02-02) claims 1-59, 86, 87 -----	1-22
X	page 5, line 20 - page 6, line 27 -----	1-6, 14-22
Y	WO 2004/039948 A (WYETH CORP [US]; WOLFMAN NEIL M [US]; BOUXSEIN MARY L [US]) 13 May 2004 (2004-05-13)	1-22
X	the whole document ----- - / --	1-6, 14-22



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the International search

Date of mailing of the International search report

15 July 2008

25/07/2008

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fayos, Cecile

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2007/025868

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>HARRISON C A ET AL: "Antagonists of activation signaling: mechanisms and potential biological applications" TRENDS IN ENDOCRINOLOGY AND METABOLISM., ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 16, no. 2, 1 March 2005 (2005-03-01) pages 73-78, XP004768099 ISSN: 1043-2760 the whole document</p> <p>-----</p>	1-22
Y	<p>WO 2005/009460 A (MEDEXIS S A [GR] ; FOTSIDIS THEODORE [GR]) 3 February 2005 (2005-02-03) page 6, line 19 - line 24</p> <p>-----</p>	1-22
Y	<p>WELT C K ET AL: "Activin: an endocrine or paracrine agent?" EUROPEAN JOURNAL OF ENDOCRINOLOGY / EUROPEAN FEDERATION OF ENDOCRINE SOCIETIES NOV 1998, vol. 139, no. 5, November 1998 (1998-11) pages 469-471, XP002488144 ISSN: 0804-4643 page 139, left-hand column, last paragraph</p> <p>-----</p>	1-22
Y	<p>COERVER K A ET AL: "Activation signaling through activin receptor type II causes the cachexia-like symptoms in inhibitor-deficient mice." MOLECULAR ENDOCRINOLOGY (BALTIMORE, MD.) MAY 1996, vol. 10, no. 5, May 1996 (1996-05), pages 534-543, XP002488145 ISSN: 0888-8809 the whole document</p> <p>page 540, right-hand column, lines 2-5</p> <p>-----</p>	1-22
P, X	<p>LI QINGLEI ET AL: "Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibitor-deficient mice following administration of a chimeric activation receptor type II-murine Fc protein." MOLECULAR HUMAN REPRODUCTION SEP 2007, vol. 13, no. 9, September 2007 (2007-09) pages 675-683, XP009102916 ISSN: 1360-9947 the whole document</p> <p>-----</p>	1-22

INTERNATIONAL SEARCH REPORT

Information on **patent family** members

International application No

PCT/US2007/025868

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 2007062188	A	31-05-2007	AU	2006318449 A1		31-05-2007
WO 2006012627	A	02-02-2006	AU	2005266875 A1		02-02-2006
			CA	2574777 A1		02-02-2006
			EP	1771470 A2		11-04-2007
			JP	2008507288 T		13-03-2008
WO 2004039948	A	13-05-2004	AU	2003279817 A1		25-05-2004
			BR	0315645 A		30-08-2005
			CA	2501180 A1		13-05-2004
			EP	1572961 A2		14-09-2005
			JP	2006516886 T		13-07-2006
			MX	PA05004224 A		20-09-2005
WO 2005009460	A	03-02-2005		NONE		